Particle.news
Download on the App Store

Germany’s Drug Policy Commissioner Hendrik Streeck Draws Fire Over Costly Therapies for the Very Old

The dispute centers on balancing rising drug costs with decisions guided by prognosis and patient will.

Overview

  • In a WELT TV appearance, Streeck questioned prescribing very expensive medications to very old patients and called for clearer, binding guidance within medical self-governance.
  • He pointed to advanced cancers and a hypothetical 10% mortality reduction study as examples, asking whether a 100-year-old should receive such therapies, while citing his father’s end-of-life care.
  • Green lawmaker Janosch Dahmen labeled the idea legally, medically and economically unsound, FDP deputy Wolfgang Kubicki denounced it as "cold cynicism," and SPD’s Karl Lauterbach rejected age-based rationing as unethical.
  • The Federal Medical Association welcomed the discussion but stressed that treatment should be based on patient preferences, prognosis and quality of life rather than age or cost.
  • Reporters noted that any formal changes would go through the Gemeinsamer Bundesausschuss, health spending was estimated at €538 billion in 2024, and no policy or guideline changes have been announced.